Harvard Combined Orthopedic Residency Program, Boston, MA, USA.
Brigham and Women's Hospital, Boston, MA, USA.
Foot Ankle Int. 2019 Nov;40(11):1260-1266. doi: 10.1177/1071100719863711. Epub 2019 Jul 18.
In 2016, our provider group adopted an initial prescription opioid maximum guideline to reduce overprescription of opioids. The purpose of this study was to prospectively assess opioid consumption patterns following implementation of this guideline in patients undergoing outpatient foot and ankle surgery.
Over a 1-year period, we prospectively analyzed opioid prescription and use patterns of 303 consecutive patients. Opioid consumption was verified by pill counts completed at the 2- and 6-week postoperative visits. The morphine equivalent dose was calculated for each prescription and converted to the equivalent 5-mg oxycodone "pill." We used the regression coefficients from a regression model of opioid consumption to create a revised guideline for maximum initial opioid prescriptions based on patient age, bony vs nonbony procedure, and anatomic location (forefoot/midfoot/hindfoot/ankle).
On average, 37.4 pills were prescribed and 18.9 pills used (47.6% utilization). Only 17.2% of patients used their full prescription quantity. By 2 weeks, 88% of patients no longer used opioids. Only 1.3% of patients used prescription opioids beyond 6 weeks. Independent risk factors for increased opioid consumption were younger age ( = .003), male sex ( = .007), recent preoperative opioid use ( = .019), bony procedures ( < .001), and ankle/hindfoot procedures ( = .016 and < .001).
This study showed the amount of opioid consumption for patients undergoing foot and ankle procedures. We present a modified guideline for the maximum initial prescription of opioids following outpatient foot and ankle procedures that can be used as a benchmark for further study in decreasing overprescribing.
Level II, prospective observational cohort study.
2016 年,我们的医疗服务机构采用了初始阿片类药物最大处方指南,以减少阿片类药物的过度处方。本研究旨在前瞻性评估该指南实施后门诊足踝手术患者的阿片类药物使用模式。
在为期 1 年的时间里,我们前瞻性分析了 303 例连续患者的阿片类药物处方和使用模式。通过术后 2 周和 6 周的随访时完成的药片计数来验证阿片类药物的消耗情况。为每个处方计算了吗啡等效剂量,并转换为等效的 5 毫克羟考酮“药丸”。我们使用阿片类药物消耗的回归模型的回归系数,根据患者年龄、骨与非骨手术以及解剖部位(前足/中足/后足/踝关节),为最大初始阿片类药物处方制定了修订指南。
平均开处 37.4 片,使用 18.9 片(利用率为 47.6%)。只有 17.2%的患者使用了全部处方量。到第 2 周时,88%的患者不再使用阿片类药物。只有 1.3%的患者在 6 周后继续使用处方阿片类药物。阿片类药物消耗增加的独立危险因素包括年龄较小( <.001)、男性( <.001)、术前近期使用阿片类药物( <.001)、骨手术( <.001)和踝关节/后足手术( <.016 和 <.001)。
本研究显示了接受足踝手术患者的阿片类药物消耗量。我们提出了一种用于门诊足踝手术后阿片类药物初始最大处方的修正指南,可以作为进一步减少过度处方的研究基准。
II 级,前瞻性观察队列研究。